论文部分内容阅读
目的观察细胞因子诱导杀伤细胞联合树突状细胞(DC-CIK)生物治疗辅助化疗对胃癌术后患者的治疗效果。方法将180例胃癌患者根据治疗方式不同分为观察组和对照组,观察组患者应用DC-CIK联合胃癌根治术及TP方案(紫杉醇+顺铂)化疗,对照组患者仅采用胃癌根治术及TP方案化疗,观察并比较两组患者的不良反应发生情况和3年生存率。结果两组患者治疗后干扰素γ(INF-γ)水平均高于治疗前(均P<0.05)。两组患者不良反应发生率差异无统计学意义(P>0.05);两组患者3年总生存率差异无统计学意义(P>0.05)。观察组患者的进展期生存率明显高于对照组,差异有统计学意义(P<0.05)。结论 DC-CIK生物治疗辅助胃癌术后化疗能够提高细胞因子水平,并且可有效地提高胃癌术后患者进展期生存率。
Objective To observe the effect of adjuvant chemotherapy with cytokine-induced killer cells and dendritic cells (DC-CIK) on postoperative patients with gastric cancer. Methods 180 cases of gastric cancer patients were divided into observation group and control group according to different treatment methods. Patients in observation group were treated with DC-CIK combined with radical gastrectomy and TP regimen (paclitaxel + cisplatin). Patients in control group were treated with radical gastrectomy and TP Chemotherapy, observed and compared two groups of patients with adverse reactions and 3-year survival rate. Results The levels of INF-γ in both groups were significantly higher than those before treatment (all P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). There was no significant difference in the 3-year overall survival rate between the two groups (P> 0.05). The survival rate of patients in the observation group was significantly higher than that in the control group, the difference was statistically significant (P <0.05). Conclusions DC-CIK biotherapy is an adjunct to gastric cancer chemotherapy, which can increase the level of cytokines, and can effectively improve the survival rate of postoperative patients with gastric cancer.